Delivery Order SPE2DB24D3013-SPE2DB25FFNYF
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,651.25 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitive award, which carries no set-aside designation, is issued under firm fixed pricing and represents a child order to AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will...
- The Defense Logistics Agency awarded a $26,543.31 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 mL pens (2 mL units). This firm fixed-price contract, which carries no set-aside designation, is classified as a delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters, with an ultimate...
- The Defense Logistics Agency awarded a $63,152.32 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 4, 2025, with completion expected by August 5, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,219.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 25, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a delivery order valued at $3,418.92 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectables on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and is being fulfilled from AmerisourceBergen's place of business in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Dupixent 300 mg/2 mL pens totaling $20,114.60 with completion scheduled for July 22, 2025. This competitive, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- The Defense Logistics Agency awarded a delivery order valued at $13,253.95 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child action under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $12,041.74. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $46,237.16. This firm fixed-price delivery order, with an ultimate completion date of July 31, 2025, represents a competitively awarded, non-set-aside procurement executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $12,151.38 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFNYFDelivery Order
The Defense Logistics Agency awarded a $3,600.92 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication indicated for multiple inflammatory conditions including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, making it a critical pharmaceutical supply for military and veteran healthcare systems supported by DLA. This delivery order exemplifies the routine pharmaceutical procurement activities executed under AmerisourceBergen's comprehensive prime vendor agreement, which enables the company to supply specialty medications, brand-name and generic drugs, and other medical commodities to support Defense Health Agency and other federal healthcare programs globally. The contract demonstrates AmerisourceBergen's established capability to fulfill competitive federal medical supply requirements through its extensive pharmaceutical distribution infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 8/1/25 |